ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Sells $794,567.55 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam sold 12,855 shares of the business’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $61.81, for a total transaction of $794,567.55. Following the sale, the chief operating officer now owns 732,620 shares of the company’s stock, valued at approximately $45,283,242.20. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Muthusamy Shanmugam also recently made the following trade(s):

• On Friday, May 17th, Muthusamy Shanmugam sold 5,836 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $62.09, for a total transaction of $362,357.24.
• On Wednesday, May 15th, Muthusamy Shanmugam sold 14,850 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $65.86, for a total transaction of $978,021.00.
• On Friday, April 19th, Muthusamy Shanmugam sold 16,809 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $65.17, for a total transaction of $1,095,442.53.
• On Wednesday, April 17th, Muthusamy Shanmugam sold 9,520 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $65.40, for a total transaction of $622,608.00.
• On Monday, April 15th, Muthusamy Shanmugam sold 7,414 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $66.33, for a total transaction of $491,770.62.
• On Thursday, March 7th, Muthusamy Shanmugam sold 15,085 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.35, for a total value of $1,000,889.75.
• On Tuesday, March 5th, Muthusamy Shanmugam sold 10,093 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.35, for a total value of $659,577.55.

ANI Pharmaceuticals Stock Down 0.1 %

ANIP stock opened at $61.66 on Thursday. ANI Pharmaceuticals, Inc. has a twelve month low of $44.27 and a twelve month high of $70.81. The company has a quick ratio of 3.12, a current ratio of 3.95 and a debt-to-equity ratio of 0.63. The stock has a market cap of $1.29 billion, a P/E ratio of 38.54 and a beta of 0.80. The business’s 50-day moving average price is $66.50 and its 200-day moving average price is $59.62.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 17.15% and a net margin of 6.87%. The firm had revenue of $131.65 million for the quarter, compared to analysts’ expectations of $123.02 million. On average, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Capital One Financial assumed coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They issued an “overweight” rating and a $80.00 price objective for the company. Guggenheim reissued a “buy” rating and issued a $77.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, April 23rd. Truist Financial raised their target price on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Finally, HC Wainwright raised their target price on ANI Pharmaceuticals from $83.00 to $87.00 and gave the stock a “buy” rating in a research report on Monday, May 13th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $81.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ANIP. Pacer Advisors Inc. purchased a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at about $41,000. AJOVista LLC bought a new stake in ANI Pharmaceuticals during the 4th quarter valued at approximately $58,000. SG Americas Securities LLC bought a new stake in ANI Pharmaceuticals during the 1st quarter valued at approximately $106,000. China Universal Asset Management Co. Ltd. raised its stake in ANI Pharmaceuticals by 361.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,367 shares of the specialty pharmaceutical company’s stock valued at $131,000 after purchasing an additional 1,854 shares during the period. Finally, ADAR1 Capital Management LLC bought a new stake in ANI Pharmaceuticals during the 4th quarter valued at approximately $132,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.